Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07444398

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

This study will compare the outcomes of Vericuguat and placebo in patient with decompensated heart failure . This study will carry out after approval from IERB. Seventy patients fulfilling the inclusion criteria will be enrolled from emergency department. Informed consent will be taken from attendants. A detailed history including name, age, gender, duration of heart failure, history of alcoholism, smoking, diabetes, hypertension, EF at baseline and NYHA class will be noted. Patients will be randomly divided in two groups by using lottery method. Outcomes will be assessed at in terms of hospitalization for heart failure, death from cardiovascular event and side effects.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Decompensated Heart Failure Cardiovascular Diseases Disease Attributes Emergencies Heart Diseases Heart Failure Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

25 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Armed Forces Institute of Cardiology. Pakistan

Rawalpindi, Punjab Province, 46000, Pakistan

Location status: Recruiting

Location contact

Prof Dr Muhammad Nadir Khan, MBBS, FCPS

CONTACT

[email protected]

+923219156153

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with decompensated heart failure (patients with left ventricular ejection fraction ≤45% presenting with NYHA functional class III-IV symptoms or worsening class II symptoms. Along with elevated natriuretic peptide levels defined as NT-proBNP >1000 pg/mL in patients with sinus rhythm and >1600 pg/mL in patients with atrial fibrillation in the absence of alternative causes of biomarker elevation)

Exclusion criteria

  • Patients with blood pressure <100 mmHg;
  • concurrent or anticipated use of long-acting nitrates, soluble guanylate cyclase stimulators, or phosphodiesterase type 5 inhibitors
  • use of intravenous inotropes or implantable left ventricular assist devices (on medical record)

Treatment and study plan

Vericiguat tablet

Drug

Group A, patients will be prescribed 2.5 mg of vericiguat. Dose will be increased to 5 mg and ultimately to the target dose of 10 mg once daily, as guided by evaluation of blood pressure and clinical symptoms along with standard treatment (sacubitril-valsartan)

Sacubitril / Valsartan

Drug

Group A Patients it will be prescribed along with vericiguat but group B patients will have (sacubitril-valsartan) as standard treatment

Primary outcomes

  1. Requirement of hospitalization for heart failure

    Time frame: 03 months

    If Ejection Fraction further reduced and patient need to admit in the hospital for symptoms including pedal edema, pleural effusion, and need intravenous diuretic therapy

  2. Death from cardiovascular event

    Time frame: 03 months

    If patient will die during 3 months follow-up

Secondary outcomes

  1. Side effects

    Time frame: 03 months

    If patient will complaint of mild to moderate gastrointestinal disturbances, Hypotension (BP≥100/60 mmHg) or any other adverse event during 3 months follow-up

Study contacts

Contact information is provided by the study sponsor or research team.

Dr Khawaja Danish Ali, MBBS

CONTACT

[email protected]

+923448890893

Sponsors and collaborators

Lead sponsor

Khawaja Danish Ali

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 2, 2026
Registry last updated
Mar 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.